CDG syndrome type 2

Congenital Disorders of Glycosylation Type II (CDG-II), also known as CDG syndrome type 2, is a group of inherited metabolic disorders that affect the process of glycosylation. Glycosylation is the enzymatic process that attaches glycans (sugars) to proteins or lipids, a critical function in the development and maintenance of various bodily systems. CDG-II is characterized by a defect in the glycosylation pathway that leads to the production of improperly glycosylated proteins.

Symptoms and Diagnosis

The symptoms of CDG-II are highly variable, depending on the specific type and severity of the disorder. Common clinical manifestations include developmental delay, intellectual disability, seizures, low muscle tone (hypotonia), abnormalities in liver function, coagulation disorders, and gastrointestinal problems. Some patients may also present with skeletal abnormalities, eye problems, and skin issues.

Diagnosis of CDG-II typically involves a combination of clinical evaluation, biochemical tests (such as transferrin isoelectric focusing), and genetic testing. The transferrin test, which assesses the pattern of glycosylation of serum transferrin, is often used as a screening tool. Confirmatory diagnosis is achieved through genetic testing, which can identify mutations in specific genes known to cause CDG-II.

Types and Genetics

CDG-II encompasses several subtypes, each associated with mutations in different genes involved in the glycosylation pathway. These genes include, but are not limited to, MOGS (CDG-IIa), MGAT2 (CDG-IIb), and SLC35C1 (CDG-IIc). The inheritance pattern of CDG-II is typically autosomal recessive, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder.

Treatment and Management

There is no cure for CDG-II, and treatment is primarily supportive and symptomatic. Management strategies may include physical therapy, occupational therapy, and speech therapy to address developmental delays and motor skills deficits. Nutritional support, management of coagulation disorders, and treatment of other specific symptoms are also important aspects of care. Regular follow-up with a multidisciplinary team of healthcare providers is essential to monitor the progression of the disorder and adjust treatment as necessary.

Research and Future Directions

Research into CDG-II is ongoing, with efforts focused on better understanding the molecular basis of the disorder, developing more effective diagnostic methods, and exploring potential therapeutic approaches. Advances in genetic and biochemical research hold promise for the development of targeted therapies that could correct the underlying glycosylation defects in CDG-II.

This metabolic pathology related article is a stub. You can help WikiMD by expanding it.